EcoDrugPlus

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSONIG00000042918
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSONIG00000020048
Gene Symbol: PSMB8
4 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSONIG00000019752
Gene Symbol: PSMD4A
1 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSONIG00000001163
Gene Symbol: PSMC1
4 Cross references
282 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSONIG00000008060
Gene Symbol: PSMC2
1 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSONIG00000017062
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSONIG00000031505
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSONIG00000035978
Gene Symbol: PSMC5
3 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSONIG00000001657
Gene Symbol: PSMC6
1 Cross references
242 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSONIG00000002599
Gene Symbol: PSMD1
4 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSONIG00000006439
Gene Symbol: PSMD11
1 Cross references
207 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSONIG00000006489
Gene Symbol: PSMD12
4 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).